The VOYXACT® Impact
A significant reduction of protein in your urine.
VOYXACT reduced proteinuria by 50% vs
a 2% increase
with placebo at 9 months.
Change in proteinuria at 9 months of treatment (n = 320).*
The results in this graph are based on an analysis of the first 320 adults in the trial at 9 months. This study is ongoing. These results were consistent across sex, age, race, ethnicity, and geographic region. At the beginning of the trial, participants had a mean uPCR-24h of 1.5 g/g.
VOYXACT was studied in adults with primary IgA nephropathy who are at risk for their disease getting worse.
510 adults with IgA nephropathy were studied in the VISIONARY clinical trial, all with reduced kidney function and protein in their urine.
Adults were randomly assigned into 2 groups—about half received an injection of VOYXACT, and about half received a placebo injection (no active medicine).
Almost all participants (98%) were also receiving the maximum tolerated dose of blood pressure medications (ACE inhibitors and/or ARBs).
Many (40%) were also taking blood sugar–lowering medications (SGLT2 inhibitors).
510 adults with IgA nephropathy were studied in the VISIONARY clinical trial, all with reduced kidney function and protein in their urine.
Adults were randomly assigned into 2 groups—about half received an injection of VOYXACT, and about half received a placebo injection (no active medicine).
Almost all participants (98%) were also receiving the maximum tolerated dose of blood pressure medications (ACE inhibitors and/or ARBs).
Many (40%) were also taking blood sugar–lowering medications (SGLT2 inhibitors).
IgA=immunoglobulin A.
ACE inhibitors=angiotensin-converting enzyme inhibitors.
ARBs=angiotensin receptor blockers.
SGLT2 inhibitors=sodium-glucose cotransporter 2 inhibitors.
Side effects for people taking VOYXACT were similar to those on placebo.
The safety of VOYXACT was evaluated in 510 patients with IgA nephropathy.
